

TRANSFORMING RADIATION PROCTOPATHY MANAGEMENT: REAL-WORLD EVIDENCE ON PURASTAT FROM A UK TEACHING HOSPITAL

Vinoth Nadesalingam Vinoth Nadesalingam

UEG Week Berlin 2025

Presentation

Colorectal

Digestive Oncology

Endoscopy

Histopathology

October 6, 2025

In a 100-patient UK series, PuraStat achieved 100% symptomatic relief in radiation proctopathy both as first-line therapy and after APC failure, with no adverse events and mean 1.3–1.5 repeat sessions over 6 months.

KEY POINTS

- All 100 patients achieved complete symptomatic relief or bleeding control, including 50 treatment-naïve patients and 50 with persistent symptoms after prior APC (median 3 prior APC sessions).
- Mean repeat endoscopic sessions were 1.3 in the de novo PuraStat group and 1.5 in the APC-to-PuraStat group over 6 months, significantly reducing the need for frequent interventions.
- Follow-up sigmoidoscopy in the de novo group showed mucosal healing or mild residual proctitis in 92% of patients.
- No adverse events such as perforation, infection, or severe pain were reported in either cohort.
- Patients with severe radiation-associated vascular ectasia and refractory bleeding demonstrated excellent response to PuraStat.
- The authors conclude that larger prospective, multicentre studies and cost-effectiveness analyses are warranted to define PuraStat's optimal place in treatment algorithms.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/047d57e4-a816-11f0-be63-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.